Exact Mass: 532.2198
Exact Mass Matches: 532.2198
Found 207 metabolites which its exact mass value is equals to given mass value 532.2198
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ponatinib
Ponatinib is a Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012 (DB08901). L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
4-[(beta-D-glucopyranosyl)oxy]-2-(hydroxymethyl)-3-(3-methylbut-2-en-1-yl)phenyl beta-D-glucopyranoside|clemomandshuricoside C
His Val Tyr Asp
Asn Asp Glu Arg
Ala Glu Gln Trp
Ala Glu Trp Gln
Ala Gln Glu Trp
Ala Gln Trp Glu
Ala Trp Glu Gln
Ala Trp Gln Glu
Cys Pro Gln Trp
Cys Pro Trp Gln
Cys Gln Pro Trp
Cys Gln Trp Pro
Cys Trp Pro Gln
Cys Trp Gln Pro
Asp Asp Gln Arg
Asp Asp Arg Gln
Asp Glu Asn Arg
Asp Glu Arg Asn
Asp His Val Tyr
Asp His Tyr Val
Asp Asn Glu Arg
Asp Asn Arg Glu
Asp Asn Val Trp
Asp Asn Trp Val
Asp Gln Asp Arg
Asp Gln Arg Asp
Asp Arg Asp Gln
Asp Arg Glu Asn
Asp Arg Asn Glu
Asp Arg Gln Asp
Asp Val His Tyr
Asp Val Asn Trp
Asp Val Trp Asn
Asp Val Tyr His
Asp Trp Asn Val
Asp Trp Val Asn
Asp Tyr His Val
Asp Tyr Val His
Glu Ala Gln Trp
Glu Ala Trp Gln
Glu Asp Asn Arg
Glu Asp Arg Asn
Glu Glu Gln Gln
Glu Phe His Thr
Glu Phe Thr His
Glu His Phe Thr
Glu His Thr Phe
Glu Asn Asp Arg
Glu Asn Arg Asp
Glu Gln Ala Trp
Glu Gln Glu Gln
Glu Gln Gln Glu
Glu Gln Trp Ala
Glu Arg Asp Asn
Glu Arg Asn Asp
Glu Thr Phe His
Glu Thr His Phe
Glu Trp Ala Gln
Glu Trp Gln Ala
Phe Glu His Thr
Phe Glu Thr His
Phe His Glu Thr
Phe His Thr Glu
Phe Thr Glu His
Phe Thr His Glu
His Asp Val Tyr
His Asp Tyr Val
His Glu Phe Thr
His Glu Thr Phe
His Phe Glu Thr
His Phe Thr Glu
His Thr Glu Phe
His Thr Phe Glu
His Val Asp Tyr
His Tyr Asp Val
His Tyr Val Asp
Asn Asp Arg Glu
Asn Asp Val Trp
Asn Asp Trp Val
Asn Glu Asp Arg
Asn Glu Arg Asp
Asn Arg Asp Glu
Asn Arg Glu Asp
Asn Val Asp Trp
Asn Val Trp Asp
Asn Trp Asp Val
Asn Trp Val Asp
Pro Cys Gln Trp
Pro Cys Trp Gln
Pro Gln Cys Trp
Pro Gln Trp Cys
Pro Trp Cys Gln
Pro Trp Gln Cys
Gln Ala Glu Trp
Gln Ala Trp Glu
Gln Cys Pro Trp
Gln Cys Trp Pro
Gln Asp Asp Arg
Gln Asp Arg Asp
Gln Glu Ala Trp
Gln Glu Glu Gln
Gln Glu Gln Glu
Gln Glu Trp Ala
Gln Pro Cys Trp
Gln Pro Trp Cys
Gln Gln Glu Glu
Gln Arg Asp Asp
Gln Trp Ala Glu
Gln Trp Cys Pro
Gln Trp Glu Ala
Gln Trp Pro Cys
Arg Asp Asp Gln
Arg Asp Glu Asn
Arg Asp Asn Glu
Arg Asp Gln Asp
Arg Glu Asp Asn
Arg Glu Asn Asp
Arg Asn Asp Glu
Arg Asn Glu Asp
Arg Gln Asp Asp
Ser Thr Tyr Tyr
Ser Tyr Thr Tyr
Ser Tyr Tyr Thr
Thr Glu Phe His
Thr Glu His Phe
Thr Phe Glu His
Thr Phe His Glu
Thr His Glu Phe
Thr His Phe Glu
Thr Ser Tyr Tyr
Thr Tyr Ser Tyr
Thr Tyr Tyr Ser
Val Asp His Tyr
Val Asp Asn Trp
Val Asp Trp Asn
Val Asp Tyr His
Val His Asp Tyr
Val His Tyr Asp
Val Asn Asp Trp
Val Asn Trp Asp
Val Trp Asp Asn
Val Trp Asn Asp
Val Tyr Asp His
Val Tyr His Asp
Trp Ala Glu Gln
Trp Ala Gln Glu
Trp Cys Pro Gln
Trp Cys Gln Pro
Trp Asp Asn Val
Trp Asp Val Asn
Trp Glu Ala Gln
Trp Glu Gln Ala
Trp Asn Asp Val
Trp Asn Val Asp
Trp Pro Cys Gln
Trp Pro Gln Cys
Trp Gln Ala Glu
Trp Gln Cys Pro
Trp Gln Glu Ala
Trp Gln Pro Cys
Trp Val Asp Asn
Trp Val Asn Asp
Tyr Asp His Val
Tyr Asp Val His
Tyr His Asp Val
Tyr His Val Asp
Tyr Ser Thr Tyr
Tyr Ser Tyr Thr
Tyr Thr Ser Tyr
Tyr Thr Tyr Ser
Tyr Val Asp His
Tyr Val His Asp
Tyr Tyr Ser Thr
Tyr Tyr Thr Ser
BENZOIC ACID, 4-[4-[(3R)-3-[[[2-OXO-2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]ETHYL]AMINO]CARBONYL]-1-PYRROLIDINYL]-1-PIPERIDINYL]-, METHYL ESTER
Bis(tert-butoxy)bis(1-methoxy-2-methyl-2-propoxy)hafnium(IV)
Onvansertib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C177899 - PLK1 Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1,2,4-triazolo(4,3-a)pyridin-3-yl)ethynyl)-
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Ponatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-4-fluoro-N-methylbenzenesulfonamide
IPN60090
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1?(GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2].